GlassScriptPhysician profile
Alexandra Steininger
NPI 1972080786
$1,767.55
in general payments reported to CMS, 2019-2025
26 companies · $798 in 2025
The $798 reported for 2025 was more than what 95% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.41 · 2022: $13.48 · 2023: $304 · 2024: $637 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,739.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $238.77 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $216.97 | 2023-2025 | Caplyta |
| Pfizer INC. | $159.26 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $141.39 | 2024-2025 | Zenpep |
| Vanda Pharmaceuticals INC. | $117.21 | 2025 | Fanapt |
| Lundbeck LLC | $94.90 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $83.10 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Alnylam Pharmaceuticals INC. | $78.26 | 2024-2025 | Onpattro |
| Glaxosmithkline, LLC. | $66.43 | 2023-2024 | Bexsero |
| Astrazeneca Pharmaceuticals LP | $65.16 | 2024-2025 | Airsupra |
| Viiv Healthcare Company | $59.19 | 2024 | Apretude |
| Phathom Pharmaceuticals, INC. | $49.06 | 2024 | Voquezna |
| Ardelyx, INC. | $47.15 | 2023-2024 | Ibsrela |
| Lilly USA, LLC | $43.68 | 2025 | Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $41.77 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $40.23 | 2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Nestle Healthcare Nutrition INC. | $37.53 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $31.14 | 2024 | |
| Uswm, LLC | $29.32 | 2023 | Lucemyra, Zimhi |
| Alkermes, INC. | $24.81 | 2025 | Aristada, Lybalvi |
| Ars Pharmaceuticals Operations, INC. | $21.23 | 2025 | Neffy |
| Janssen Pharmaceuticals, INC | $18.35 | 2025 | Invega Sustenna |
| Novo Nordisk INC | $17.78 | 2025 | Ozempic |
| Seqirus USA INC | $16.84 | 2025 | Flucelvax, Fluad |
| Sanofi Pasteur INC. | $14.41 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.61 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Steininger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.